News | May 29, 2024
Lilly increases manufacturing investment to US$ 9 billion at newest Indiana site
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
Sales reflect continued strong growth in oncology and vaccines
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
Fluid bed processes: drying, granulating, and coating in just one product container
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Subscribe To Our Newsletter & Stay Updated
